Tiltan Pharma Company
Tiltan Pharma is an Israeli biopharmaceutical company, established in 2006, that developed a proprietary anti-angiogenic and immune modulatory platform technology, for the treatment of cancer. The platform technology was originally developed by Prof. Shmuel (Muli) Ben Sasson from the Hebrew University.
Technology:
P4 Medicine
Industry:
Preventive Medicine
Headquarters:
Jerusalem, Israel
Founded Date:
2006
Employees Number:
1-10
Funding Status:
N/A
Total Funding:
$1.5M
Last Funding Type:
Venture - Series Unknown
Register and Claim Ownership